Search Results - "SMITH, Larry R"

The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397 by Dietl, Anna-Maria, Misslinger, Matthias, Aguiar, Mario M, Ivashov, Vasyl, Teis, David, Pfister, Joachim, Decristoforo, Clemens, Hermann, Martin, Sullivan, Sean M, Smith, Larry R, Haas, Hubertus

“…VL-2397 (previously termed ASP2397) is an antifungal, aluminum-chelating cyclic hexapeptide with a structure analogous to that of ferrichrome-type…”
Get full text

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial by Kharfan-Dabaja, Mohamed A, MD, Boeckh, Michael, Prof, Wilck, Marissa B, MBChB, Langston, Amelia A, Prof, Chu, Alice H, MS, Wloch, Mary K, PhD, Guterwill, Don F, BSMT, Smith, Larry R, PhD, Rolland, Alain P, PhD, Kenney, Richard T, Dr

“…Summary Background Cytomegalovirus reactivation occurs within 6 months in 60–70% of cytomegalovirus-seropositive patients after allogeneic haemopoietic…”
Get full text

First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults by Mammen, Mammen P, Armas, Danielle, Hughes, Frank H, Hopkins, Andrew M, Fisher, Cindy L, Resch, Pamela A, Rusalov, Denis, Sullivan, Sean M, Smith, Larry R

“…VL-2397 is an antifungal drug with a novel mechanism of action, rapid fungicidal activity, and potent activity against , including azole-resistant strains…”
Get full text

Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects by Wloch, Mary K., Smith, Larry R., Boutsaboualoy, Souphaphone, Reyes, Luane, Han, Christina, Kehler, Jackie, Smith, Heather D., Selk, Linda, Nakamura, Ryotaro, Brown, Janice M., Marbury, Thomas, Wald, Anna, Rolland, Alain, Kaslow, David, Evans, Thomas, Boeckh, Michael

“…Background. VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to…”
Get full text

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans by Sandbulte, Matthew R, Jimenez, Gretchen S, Boon, Adrianus C M, Smith, Larry R, Treanor, John J, Webby, Richard J

“…A pandemic H5N1 influenza outbreak would be facilitated by an absence of immunity to the avian-derived virus in the human population. Although this condition…”
Get full text

Plasmid DNA-Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus by Lalor, Peggy A., Webby, Richard J., Morrow, Jane, Rusalov, Denis, Kaslow, David C., Rolland, Alain, Smith, Larry R.

“…Plasmid DNA (pDNA) vaccines represent an alternative to conventional inactivated influenza vaccines that are likely to experience supply constraints during a…”
Get full text

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients by Ljungman, Per, Bermudez, Arancha, Logan, Aaron C., Kharfan-Dabaja, Mohamed A., Chevallier, Patrice, Martino, Rodrigo, Wulf, Gerald, Selleslag, Dominik, Kakihana, Kazuhiko, Langston, Amelia, Lee, Dong-Gun, Solano, Carlos, Okamoto, Shinichiro, Smith, Larry R., Boeckh, Michael, Wingard, John R., Cywin, Beth, Fredericks, Christine, Lademacher, Christopher, Wang, Xuegong, Young, James, Maertens, Johan

“…Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids…”
Get full text

Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial by Smith, Larry R, Wloch, Mary K, Chaplin, Jennifer A, Gerber, Michele, Rolland, Alain P

“…2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This…”
Get full text

Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus by Hartikka, Jukka, Bozoukova, Vesselina, Morrow, Jane, Rusalov, Denis, Shlapobersky, Mark, Wei, Qun, Boutsaboualoy, Sou, Ye, Ming, Wloch, Mary K., Doukas, John, Sullivan, Sean M., Rolland, Alain, Smith, Larry R.

“…Human cytomegalovirus (CMV) establishes a lifelong persistent infection characterized by periods of latency and sporadic viral replication and is a major…”
Get full text

Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects by Kovanda, Laura L, Sullivan, Sean M, Smith, Larry R, Desai, Amit V, Bonate, Pete L, Hope, William W

“…VL-2397, a novel, systemic antifungal agent, has potent and fungicidal activity against species. Plasma concentrations from a phase 1 study were used to…”
Get full text

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults by Keitel, Wendy A., Treanor, John J., El Sahly, Hana M., Evans, Thomas G., Kopper, Scott, Whitlow, Vanessa, Selinsky, Cheryl, Kaslow, David C., Rolland, Alain, Smith, Larry R., Lalor, Peggy A.

“…VCL-AB01, a cationic lipid-formulated plasmid DNA (pDNA)-based vaccine that contains genes encoding genetically detoxified B. anthracis protective antigen (PA)…”
Get full text

A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells by McVoy, Michael A, Lee, Ronzo, Saccoccio, Frances M, Hartikka, Jukka, Smith, Larry R, Mahajan, Rohit, Wang, Jian Ben, Cui, Xiaohong, Adler, Stuart P

“…Abstract A vaccine to prevent congenital cytomegalovirus (CMV) infections is a national priority. Investigational vaccines have targeted the viral glycoprotein…”
Get full text

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin by Smith, Larry R, Wloch, Mary K, Ye, Ming, Reyes, Luane R, Boutsaboualoy, Souphaphone, Dunne, Casey E, Chaplin, Jennifer A, Rusalov, Denis, Rolland, Alain P, Fisher, Cindy L, Al-Ibrahim, Mohamed S, Kabongo, Martin L, Steigbigel, Roy, Belshe, Robert B, Kitt, Ernest R, Chu, Alice H, Moss, Ronald B

“…Abstract Background Development of vaccines against highly pathogenic avian influenza virus H5N1 subtypes posing a pandemic threat remains a priority…”
Get full text

Pharmacokinetics and Immunogenicity of ASP0113 in CMV‐Seronegative Dialysis Patients and CMV‐Seronegative and ‐Seropositive Healthy Subjects by Bonate, Peter L., Van Sant, Charles, Cho, Kathy, Zook, Erin C., Smith, Larry R., Boutsaboualoy, Sou, Ye, Ming, Wang, Xuegong, Wu, Ruishan, Koester, Anne, Rammelsberg, Diane, Goldwater, Ronald, Marbury, Thomas C.

“…Cytomegalovirus (CMV) infection causes significant morbidity and mortality in immunocompromised transplant patients. ASP0113, a first‐in‐class DNA vaccine…”
Get full text

Reanalysis of TransVax immunogenicity by Kharfan-Dabaja, Mohamed A, Boeckh, Michael, Wilck, Marissa B, Langston, Amelia A, Chu, Alice H, Wloch, Mary K, Smith, Larry R, Rolland, Alain P, Kenney, Richard T

Get full text

Vaxfectin® , a cationic lipid-based adjuvant for protein-based influenza vaccines by Hartikka, Jukka, Bozoukova, Vesselina, Yang, Catherine K, Ye, Ming, Rusalov, Denis, Shlapobersky, Mark, Vilalta, Adrian, Wei, Qun, Rolland, Alain, Smith, Larry R

“…Abstract Mice were immunized either with unadjuvanted seasonal trivalent influenza vaccine (TIV) or TIV formulated with Vaxfectin® , a cationic lipid-based…”
Get full text

Questionnaire for Biotechs: Vical Incorporated by Bilinsky, Igor P, Smith, Larry R

“…This feature contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected…”
Get full text

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes by Cassetti, M.Cristina, McElhiney, Sue P., Shahabi, Vafa, Pullen, Jeffrey K., Le Poole, I.Caroline, Eiben, Gretchen L., Smith, Larry R., Kast, W.Martin

“…An effective vaccine for treating human papillomavirus (HPV)-associated malignancies such as cervical cancer should elicit strong T cell-mediated immunity…”
Get full text

Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA by VELDERS, Markwin P, MCELHINEY, Sue, CASSETTI, Maria Cristina, EIBEN, Gretchen L, HIGGINS, Terry, KOVACS, Gerald R, ELMISHAD, Amira G, KAST, W. Martin, SMITH, Larry R

“…The etiological role of human papillomaviruses (HPV) in cervical and other cancers suggests that therapeutic vaccines directed against requisite viral antigens…”
Get full text

Novel microneutralization assay for HCMV using automated data collection and analysis by Abai, Anna Maria, Smith, Larry R., Wloch, Mary K.

“…In addition to being sensitive and specific, an assay for the assessment of neutralizing antibody activity from clinical trial samples must be amenable to…”
Get full text